0,1,2,3,4,5
Table 6.3.5:  Randomised controlled trials comparing salvage radiotherapy combined with androgen,,,,,
Study,n,Risk groups,"Median 
FU (mo)",Regimen,Outcome
"GETUG-AFU 16 
2019 [1044]","369 RT + ADT  
374 RT","ISUP grade 
< 2/3 89%
ISUP grade  
> 4 11% 
cN0",112,"66 Gy PBRT + 6 mo. 
LHRH analogue 
66 Gy BPRT","10-yr. 
PFS: RT + ADT, 64%
PFS: RT, 49%
p < 0.0001
MFS: RT + ADT, 75%
MFS: RT, 69%
p = 0.034"
"RTOG 9601  
2017 [1043]","384 RT + ADT  
376 RT","pT2 R1, pT3 
cN0",156,"64.8 Gy PBRT + 
bicalutamide 24 mo. 
64.8 Gy PBRT + 
placebo","12-yr. 
cumulative DM
RT + ADT: 14%
RT + placebo: 23%
p = 0.005
OS
RT + ADT: 76%
RT + placebo: 71%
p = 0.04
DSM
RT + ADT: 5.8%
RT + placebo: 13.4%
p < 0.001"
"NRG Oncology/
RTOG 0534 
SPPORT [1045]","574 SRT + 
PBRT + ADT
578 SRT + 
ADT
564 SRT","pT2 or pT3
ISUP < 5
Pre SRT  
PSA: 0.1-2.0","survivors:
8.2 years","64.8–0.2 Gy PBRT
64.8–70.2 Gy PBRT
6 mo. LHRH analogue
64.8–70.2 Gy PBRT + 
45 Gy PLNRT
6 mo. LHRH analogue","5-yr. FFP (primary 
endpoint)
70.9% Group 1
81.3% Group 2
87.4% Group 3
Comparisons :
G 3 vs. G 1:
p < 0.0001
G 2 vs. G 1
p < 0.0001
G 3 vs. G 2
p < 0.0027"
